Friday, 9 June 2017

Spared Healthy Breast Tissue after Breast Conserving Surgery for Palpable Invasive Ductal Breast Carcinoma; US Guided Versus Traditional Palpation Guided Excision

Breast Carcinoma
Breast is still the commonest site of cancer in females. Breast Conserving Surgery is providing long term survival equal to that seen with mastectomy for early stage breast cancer.

The aim of the study was to compare between US guided versus Traditional palpation guided excision in Breast Conserving Surgery for palpable invasive ductal breast carcinoma regarding the volume of spared healthy breast tissue.

This prospective study was carried out on 40 consecutive female patients with early palpable invasive breast cancer. Patients are divided into two groups.

Thursday, 8 June 2017

Nestin: A Biomarker of Aggressive Uterine Cancers

Uterine Cancers
Cancers of the uterine corpus are the most common gynecologic cancers in the United States with incidence and mortality increasing both in the United States of America and globally.

Validated biomarkers with prognostic, predictive, and/or theragnostic value will likely play a vital role in advancing assessments of risk and guiding clinical management decision making.

Nestin is a class VI intermediate filament protein that was first described as a neural stem marker and regulates the TGFβ (transforming growth factor beta) pathway. It plays a critical role in cancer cell migration, invasion, angiogenesis, and metastasis both in vitro and in vivo.

Wednesday, 7 June 2017

Osteoblastic Changes During Non-Small Cell Lung Cancer (NSCLC) Treatment

Cell Lung Cancer
Recently, we published an article reporting an example of the potential misinterpretation in the evaluation of osteoblastic changes during tyrosine-kinase inhibitor treatment in metastatic ALKrearranged non-small cell lung cancer.

Bone metastases are common in disseminated NSCLC, occurring in approximately 30% to 40% of patients. In the majority of cases, they present an osteolytic imaging pattern, even though osteoblastic or mixed-type patterns have also been reported in nearly 8% of cases. Generally, in the assessment of objective response to anticancer agents, bone metastases are classified as non-target lesions and therefore “not evaluable” for response.

However, according to the revised Response Evaluation Criteria in Solid Tumors guideline, the appearance of new non-target lesions, including lytic or osteoblastic bone metastases, is a criterion for defining progressive disease. Sometimes, the evaluation of bone lesion response may be challenging and misinterpreted.

Tuesday, 6 June 2017

Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types

Chemotherapy in Triple Negative Breast Cancer
The aim of this study was to compare the accuracy of MRI for prediction of response to Neo-adjuvant chemotherapy in Triple negative (TN) breast cancer, with respect to other molecular types.

There were a total of 1610 breast cancers diagnosed between March 2009 and August 2014, out of which 82 patients underwent MRI before and after neo-adjuvant chemotherapy but just before surgery.

Triple negative cancers were analysed with respect to others subtypes. Accuracy of MRI for prediction of pathological complete response was compared between different subtypes, by obtaining ROC curves.

Monday, 5 June 2017

Effective Personalized Treatment of Advanced Hepatic Carcinoma based on Sorafenib

Treatment of Advanced Hepatic Carcinoma
Hepatic carcinoma (HCC) has rised in China because of hepatitis B virus(HBV) effection, it has been famous for devastating malignancy as well as little treatment effect for HCC Sorafenib, has been successfully applied for solid tumors such as renal cancer, hepatocellular carcinoma.

Sorafenib used alone or combination with others can induce growth-inhibition and apoptosis in vitro experiment. Sorafenib now was suggested to advanced hepatic carcinoma patient unqualitied for hepatectomy and transplant.

A team of advanced hepatic carcinoma patients were enrolled for Sorafenib monotherapy or combination with HIAC,TACE, systemtic chemotherapy with arsenic trioxide and octreotide on base of personal disease progress CT and level of AFP were used to assess the tumor effect for decision of next treatment plan, An individualization treatment plan was performed ultimately.

Friday, 2 June 2017

The Era of Individualized Medicine in Cancer

Medicine in CancerTreatment strategies mostly based on chemoradiotherapy are not efficient for a number of cancer patients. Moreover, targeted therapy has been shown to confer benefits, in some cancer types, for only a subset of patients.

Therefore, there is a consensus among scientists and the medical community that the molecular information of a particular tumor is necessary to support clinical decisions even if considering the limited list of drugs available.

Despite the advances in the development of targeted and immunotherapies, improvement of response also rely on interpretation of tumor profile.

Thursday, 1 June 2017

Childhood Cancer Care in Developing Countries; Challenge

Childhood Cancer Care
Dealing with children who have cancer in developing countries is a great human experience not only for the patient and the family but also for persons who are caring them.

The diagnosis of a child as a cancer case is really a great shock to all family members and it is a moment of a dramatic change in their life. First reaction is usually a combination of sadness and denial.


They will start a new style of life with a plenty of investigations, appointments and different treatments decisions and plans. Different negative emotional reactions are the classic feelings of the parents every time they meet the treating physician.